Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma I alnuctamab GPRC5D iber/mezi Extending leadership in multiple myeloma: Opportunity to help patients across their treatment journey 89 Patient Segments BMS Assets Ill Bristol Myers Squibb™ Newly Diagnosed Multiple Myeloma (1L) Early Relapse and Refractory Multiple Myeloma (2L-4L) Late Relapse and Refractory Myeloma (5L+) Quadruple class exposed Post-SCT consolidation Post-SCT maintenance anti-CD38 Sensitive/Naïve Post anti-CD38 Triple class exposed Abecma (idecabtagene vicleucel) iberdomide iberdomide SUSPENSION FOR IV INFUSION Abecma [idecabtagene vicleucel] SUSPENSION FOR VINFUSION mezigdomide alnuctumab mezigdomide alnuctumab GPRC5D CAR T GPRC5D CAR T Abecma [idecabtagene vicleucel] GPRC5D CAR T SUSPENSION FOR VINFUSION ☐☐ Planned Ongoing Approved Not for Product Promotional Use 91

View entire presentation